FLT1/VEGFR1 is a vascular endothelial growth factor receptor and its ligands include VEGFA, VEGFB and PlGF. The anti-VEGFA drug bevacizumab is a standard treatment for metastatic CRC and is associated with a benefit in terms of overall survival. Here, PGF is linked to colorectal carcinoma.